Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pantoprazole 20 mg vs 40 mg for rapid symptom relief in hospitalized GERD/NERD patients
2005-004856-11Phase 3Terminated
- Sponsor
- Altana Pharma
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pantoprazole in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE) (2 arms), sponsored by Altana Pharma. Primary endpoint: Symptom reduction after 1 day. Started Jun 2006; status: terminated.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on 2005-004856-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004856-11.